The transition from 2D to 3D cell culture is a first step towards physiologically more relevant in vitro models for human (disease) modeling and preclinical drug development. Organoid and Organ-on-a-Chip technology are two fields of development that are rapidly redefining cell culture biology in the 21st century. HUB Organoids™ are excellent surrogates of patients, capable of taking on the function of the tissue of origin and modeling a wide range of diseases in the areas of oncology, infectiology, genetics and metabolism. Organ-on-a-Chip technology has demonstrated how microengineering can add aspects such as perfusion flow, patterning of tissues, extracellular matrix embedment, vascular structure, precise control over gradients and application of mechanical strain to tissue culture.
In this webinar, scientists from MIMETAS and Hubrecht Organoid Technology (HUB) will give you an introduction of HUB Organoids™, and the OrganoPlate® platform. You will learn how a combination of both technologies can be used for in vitro tissue- and disease modeling.
In this webinar, you will learn:
- Why HUB Organoids™ in OrganoPlate® have a great potential for early drug discovery and development
- Why combining organoids with organ-on-a-chip technology open new doors for (complex) tissue- and disease modelling
- Which applications combine the best of these two worlds and will inspire your research